Pierre-Olivier Lavoie

This inventor holds 21 USPTO granted patents and 20 published patent applications, plus 12 CIPO patents and 14 EPO patents, primarily in Viral Protein Engineering. Top assignees: Medicago Inc., Aramis Biotechnologies Inc., Medicago Inc. of Quebec, Canada. Active years: 2016-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Pierre-Olivier Lavoie. Retrieved from https://idiyas.com/inventor/pierre-olivier-lavoie

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 21 (Patent Applications = 20)

% Patents Active = 100.0

CIPO Patents = 12 (Patent Applications = 18)

EPO Patents = 14 (Patent Applications = 33)

Average Co-Inventor Count = 3.2

ph-index = 2

Forward Citations = 15(Granted Patents)

Location History:

Québec, CA (2016)
Quebec, CA (2016 - 2024)

Company Filing History:

Aramis Biotechnologies Inc.

patents

1 out of 1

Medicago Inc. of Quebec, Canada

patent

4. 1 out of 263

Mitsubishi Tanabe Pharma Corporation

patents

Years Active: 2016-2025

Loading Chart...

Areas of Expertise:

Influenza Virus

Hemagglutinin

Norovirus

VLPs

Plant Expression

Recombinant Proteins

CPMV Enhancer

Chimeric Particles

Transgenic Plants

Viral Proteins

Fusion Proteins

Picornavirus

21 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12428661 - Influenza virus hemagglutinin mutants (2025-09-30),

2. 12146145 - Endogenous plant expression enhancer (2024-11-19),

3. 12139511 - Influenza virus hemagglutinin mutants (2024-11-12),

4. 12104196 - Influenza virus hemagglutinin mutants (2024-10-01),

5. 12076388 - Modified norovirus VP1 proteins and VLPS comprising modified norovirus VP1 proteins (2024-09-03),

6. 11987601 - Norovirus fusion proteins and VLPs comprising norovirus fusion proteins (2024-05-21),

7. 11884929 - CPMV enhancer elements (2024-01-30),

8. 11759512 - Modified norovirus VP1 proteins and VLPs comprising modified norovirus VP1 proteins (2023-09-19),

9. 11608361 - Norovirus fusion proteins and VLPS comprising norovirus fusion proteins (2023-03-21),

10. 11602558 - Modified norovirus VP1 proteins and VLPS comprising modified norovirus VP1 proteins (2023-03-14),

11. 11441150 - CPMV enhancer elements (2022-09-13),

12. 11434497 - Recombinant influenza virus-like particles (VLPS) produced in transgenic plants (2022-09-06),

13. 10590173 - Picornavirus-like particle production in plants (2020-03-17),

14. 10563213 - Modified CPMV enhancer elements (2020-02-18),

15. 10287555 - Rotavirus-like particle production in plants (2019-05-14),

Title: Innovator Pierre-Olivier Lavoie: A Pioneer in Plant Biotechnology

Introduction

Pierre-Olivier Lavoie, based in Quebec, Canada, is a prominent inventor recognized for his significant contributions to plant biotechnology. With an impressive portfolio of 20 patents, he has been at the forefront of developing innovative solutions that influence agricultural practices and biotechnological advancements.

Latest Patents

Among his latest patents are the "Endogenous Plant Expression Enhancer," which involves an isolated expression enhancer active in plants, offering methods for enhancing gene expression. The enhancers include novel components like nbEPI42, nbSNS46, and several others, paving the way for advancements in plant genetic engineering. Another noteworthy patent is focused on "Influenza Virus Hemagglutinin Mutants," describing the production of modified influenza viral proteins in plants. This patented process aims to increase the yield of influenza virus-like particles, highlighting a method that integrates biotechnology with virology.

Career Highlights

Pierre-Olivier has garnered extensive experience in the biotechnology sector, having worked with leading companies such as Medicago Inc. and Aramis Biotechnologies Inc. His expertise in plant genetics and protein production has been instrumental in the development of cutting-edge biotechnological applications tailored for improving health outcomes and agricultural efficiencies.

Collaborations

Throughout his career, Pierre-Olivier has collaborated with several distinguished colleagues, including Marc-Andre D'Aoust and Manon Couture. These partnerships have facilitated the exchange of ideas and fostered innovations that contribute to the field of plant biotechnology and genetic modification.

Conclusion

Pierre-Olivier Lavoie's impressive track record of patents and collaborations exemplifies his dedication to advancing the field of biotechnology. His innovative approaches hold the potential to transform agricultural practices and enhance our ability to combat viral infections, making him a key player in the ongoing evolution of the science. With continued research and development, Lavoie is expected to shape the future of biotechnology in impactful ways.

Profile summary based on public USPTO records.